Home > Boards > US OTC > Medical - Healthcare >

Decision Diagnostics Corp. (DECN)

DECN RSS Feed
Add DECN Price Alert      Hide Sticky   Hide Intro
Moderator: pumper_stumper, IPwatcher
Search This Board: 
Last Post: 3/4/2021 6:51:46 PM - Followers: 418 - Board type: Free - Posts Today: 0

 

     $DECN       
https://www.otcmarkets.com/stock/DECN/profile

                                                          

On December 18, 2020, the SEC and US Dept of Justice, announced actions against DECN due to alledged false claims about the supposed Covid-19 test being developed.

https://www.sec.gov/litigation/complaints/2020/comp-pr2020-327.pdf

On April 23, 2020, the SEC announced an action against DECN, suspending trading in the company's stock for two weeks.  There is currently a SEC court case ongoing where the SEC has identified the many reasons for the suspension.

https://www.otcmarkets.com/stock/DECN/news/SEC-Suspension-of-Trading?id=260085
 

DECN Earnings History

Q1-Q3 2020 - $22,718,712-
2019 - $
3,132,295-
2018 - $2,240,220-
2017 - $2,991,404-
2016 - $2,967,357-
2015 - $2,771,345-
2014 - $1,841,010-

Total - $38,662,343-



                                     
Decision Diagnostics Corp. is a nationwide prescription and non-prescription diagnostics and home testing products distributor. We market our GenUltimate, GenSure, PetSure (test strips for dogs and cats) and GenChoice (in FDA 510(k) review), our panacea GenUltimate TBG glucose test strips and meter (in 3rd party testing), our GenPrecis test strips and meter (for private label sale), and our GenUltimate 4Pets glucose test strips and meter for the diabetic testing of dogs, cats and horses. We are also FDA approved and have complete R&D and manufacturing facilities in South Korea. We made the the first alternative glucose testing strips sold to the market in this decade and the first alternative test strip products sold into the market since early 2008.

                                                                                             
                                                                        



                                      

                                                                                                
               

Keith Berman, CEO of DECN commented, "GenViro for the Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG product line. What makes the testing for the Coronavirus possible, and the GenUltimate TBG special, is the company's Impedance measurement technology.

https://www.frontiersin.org/articles/10.3389/fmicb.2015.00940/full

While infectious disease testing and management has not previously been a part of our business model, we seized on this "do good" opportunity because our "Gen" line of products are and have been manufactured since 2016 in what is ground zero for Coronavirus (covid19) in Daegu, Korea. The company will have available samples of the blood of those previously infected available for testing as the company quickly converts its GenUltimate TBG methods and Precise meter, into a precise infectious disease testing device for the screening for Coronavirus."

                                                    



Read Recent Press Releases » 

Review Recent Financial Reports »

Visit PharmaTech Solutions, Inc. »

                                 

 


Mod Cash4 Updated Ibox 3/11/2020

NEWS
https://www.otcmarkets.com/stock/DECN/news


 

GenViro! 12-Month Forecast

Number of Months

1

2

3

4

5

6

7

8

9

10

11

12

SUM

Year 1

Apr-20

May-20

Jun-20

Jul-20

Aug-20

Sep-20

Oct-20

Nov-20

Dec-20

Jan-21

Feb-21

Mar-21

 
                           

New Facility Customers

0

0

0

0

0

5000

5000

5000

5000

5000

5000

5000

 

Retained Facilities

0

0

0

0

0

0

5000

10000

15000

20000

25000

30000

 

Total Facility Customers

0

0

0

0

0

5000

10000

15000

20000

25000

30000

35000

35,000

Kits Consumed

0

0

0

0

0

15,000,000

30,000,000

45,000,000

60,000,000

75,000,000

90,000,000

105,000,000

420,000,000

We are not resting our laurels with our GenViro development. Later product entries will be test methods for Polio, Ebola (Marburg), Bird Flu, and SARS. The cost of our test kits will be sold in a price range of $4.95 to $7.95 per use. The Coronavirus kit will be sold for $6.95. Each kit sold will carry enough diagnostic for two tests, a primary test, and a test in reserve in case of human error in administrating the primary test. We plan to provide our diagnostics initially for use at hospitals, doctors' offices, and clinics. Once production ramps up, we will offer testing kits and meters to patients for testing at-home.

Mr. Berman concluded, "As you might imagine with a product announcement of such importance, we have been contacted by a number of potential partners for our kit, as well as companies who were not chosen last time to proceed past the proposition stage. The company's first choice for partnering will be a company that made "the cut" last time for our GenUltimate! TBG product. We will discuss partnering potential in a coming release. For the moment, the company is content calling on big box and long term care chains through its existing distributors and agents."

DECN also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leding Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. The company has also just introduced its GenExpidient! Universal Translator for bio-sensor devices of different manufacture. A GenExpidient! device will be included in every Covid19 kit. Having such a device will lower the incidence of cleaning and disinfecting the GenViro! meter.

ABOUT DECISION DIAGNOSTICS CORP

Decision  

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of March 11 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973

info@decisiondiagnostics.co
www.genultimate.com
www.genultimatetbg.com
www.petsureteststrips.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.



View source version on accesswire.com:
https://www.accesswire.com/579985/DECN-Provides-First-Looks-At-Its-GenViroTM-Corona-Virus-Screening-Kit-First-Year-Product-Forecast-of-420-Million-Kits-with-Sales-Beginning-Late-3Q-2020


 

SEC Charges Biotech Company and CEO With Fraud Concerning COVID-19 Blood Testing Device
FOR IMMEDIATE RELEASE

2020-327

Washington D.C., Dec. 18, 2020 —
The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 2020.

The SEC's complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics' Covid-19 device and progress towards FDA emergency use authorization. As alleged, at the time of these claims, Decision Diagnostics lacked a proven method for detecting the virus and had no physical testing device. Further, its advisors had warned that the testing kit they were trying to manufacture would not work as Decision Diagnostics had described. The complaint also alleges that the statements created the misleading impression that the test was soon to be introduced to the market and led to surges in the price and trading volume of Decision Diagnostics' stock.

"During this unprecedented time, when the need for truthful disclosures concerning Covid-19 tests is of vital importance, Decision Diagnostics and its CEO allegedly misled investors by claiming to have made a working test device when all they had was an idea that had not materialized into a product," said Stephanie Avakian, Director of the Division of Enforcement. "With the onset of the global pandemic, we quickly pivoted to identify potential areas of fraud. This case is another example of how the Commission will hold accountable those who exploit the pandemic to harm investors."

"In our complaint, we allege that Decision Diagnostics and Berman repeatedly made baseless representations to the investing public about market-moving events like progress in obtaining FDA approval and having breakthrough technology," said Anita B. Bandy, Associate Director of the Division of Enforcement. "Today's filing is a credit to the dedicated SEC staff, who continued to investigate after the trading suspension and quickly uncovered the alleged fraud."

The complaint, filed in the U.S. District Court for the Southern District of New York, charges Decision Diagnostics and Berman with violating antifraud provisions of the securities laws. The SEC is seeking a court order permanently enjoining both Decision Diagnostics and Berman from directly or indirectly violating those provisions and ordering them to pay civil penalties.

The Department of Justice's Market Integrity and Major Frauds Unit announced today that parallel criminal charges against Berman were also filed in the U.S. District Court for the District of Columbia.

The SEC's investigation, which is continuing, has been conducted by Ernesto Amparo, Carlisle Perkins and Lesley Atkins and supervised by Jeff Leasure and Ms. Bandy with invaluable assistance by Margaret A. Cain of the Office of Market Intelligence and Hane L. Kim of the Microcap Fraud Task Force, both members of the SEC's Coronavirus Steering Committee. The litigation will be handled by James Carlson, David Misler and supervised by Tom Bednar. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.

https://www.sec.gov/news/press-release/2020-327

https://www.sec.gov/litigation/complaints/2020/comp-pr2020-327.pdf

 
DECN SECURITY DETAILS

Share Structure

 
Authorized Shares
494,995,000
 
Outstanding Shares
12/11/20 - 
349,741,793
11/06/20 - 332,025,278
10/09/20 - 325,752,685
09/11/20 -  313,434,787
08/07/20 - 305,063,608
07/10/20 - 302,663,608
05/15/20 - 267,213,123
04/03/20 - 212,000,000
03/31/20 - 199,792,833
03/06/20 - 159,999,161
12/31/19 - 156,679,161
12/31/18 - 134,551,840
12/31/17 - 110,241,640
12/31/16 - 84,639,908 

 
 
Restricted
07/10/2020 - 5,969,436
10/09/2020 - 9,983,981
 
Unrestricted
315,768,704
 

 

 
 
 
DECN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#94285  Sticky Note LINKS TO COURT DOCUMENTS IN BERMAN/DECN SECURITIES FRAUD PROCEEDINGS: IPwatcher 01/16/21 08:53:26 PM
#93495  Sticky Note SEC Charges Biotech Company and CEO With Fraud lucky,mydog 12/18/20 02:59:32 PM
#94662   Nah not really. vinovista 03/04/21 04:53:19 PM
#94661   since January 6th. Gosh did something happen on IPwatcher 03/04/21 02:11:34 PM
#94660   OK if you say so as I'm sure vinovista 03/04/21 10:53:21 AM
#94659   There is no news. Pedima is not news Johnny_C 03/04/21 10:41:40 AM
#94657   1) Jeff Bezos: $140 billion. vinovista 03/04/21 09:18:45 AM
#94656   Pumper Stumper is not Berman. PlutoImploded is alleged Johnny_C 03/04/21 09:14:40 AM
#94655   "Has there been news for pumper stumper to vinovista 03/04/21 08:43:03 AM
#94654   Has there been news for pumper stumper to Johnny_C 03/04/21 08:07:15 AM
#94652   lol just Got ernie44 03/03/21 07:14:15 PM
#94651   Anyone else noticed P stump hasn't posted since IPwatcher 03/03/21 05:41:58 PM
#94650   Anyone else noticed P stump hasn't posted since Jelly Bean 03/03/21 01:28:08 PM
#94649   Anyone else noticed P stump hasn't posted since vinovista 03/03/21 12:22:45 PM
#94648   BADDDDD links to SEC ernie44 03/02/21 09:04:32 PM
#94647   So your saying I’m not going to be IPwatcher 03/02/21 08:57:37 PM
#94646   South Korea to give free COVID-19 tests to IPwatcher 03/02/21 08:48:08 PM
#94645   So your saying I’m not going to be Luka Brasi 03/02/21 08:47:47 PM
#94644   South Korea to give free COVID-19 tests to IPwatcher 03/02/21 08:28:32 PM
#94643   South Korea to give free COVID-19 tests to Luka Brasi 03/02/21 07:46:34 PM
#94642   Gottcha!! But when someone post on a public Jelly Bean 03/02/21 03:55:26 PM
#94641   Gottcha!! But when someone post on a public jimbob4 03/02/21 02:33:51 PM
#94640   There ya go... you naliled it. Just because Johnny_C 03/02/21 01:31:24 PM
#94639   maybe someone that claims to have a net Johnny_C 03/02/21 01:22:06 PM
#94638   There is a few evenings bedtime reading there rawman 03/02/21 01:17:58 PM
#94637   The full text of the EU Medical Device IPwatcher 03/02/21 01:05:38 PM
#94636   Yeah, well its not equivalent to selling genviro IPwatcher 03/02/21 12:49:43 PM
#94635   CE mark is not equivalent to FDA. rawman 03/02/21 12:42:56 PM
#94634   Lost ??? Im way up from .01 like Jelly Bean 03/02/21 12:34:36 PM
#94633   CE mark is not equivalent to FDA. Jelly Bean 03/02/21 12:31:50 PM
#94632   To vague. vinovista 03/02/21 12:24:06 PM
#94631   Does any one know what the requirements are rawman 03/02/21 12:20:22 PM
#94630   At one point, based on a false Zillow vinovista 03/02/21 12:15:44 PM
#94629   Sorry, but it looks like anything I wrote Johnny_C 03/02/21 12:05:27 PM
#94628   Have you applied for that position? vinovista 03/02/21 11:58:12 AM
#94627   think dynamically and abstractly in a multidimensional perspective. Johnny_C 03/02/21 11:47:06 AM
#94626   Linear thinking is not apropos, one needs to vinovista 03/02/21 11:21:24 AM
#94625   Does any one know what the requirements are vinovista 03/02/21 10:54:41 AM
#94624   Keep trying. vinovista 03/02/21 10:45:35 AM
#94623   I have a funny feeling that it won't Johnny_C 03/02/21 10:24:56 AM
#94622   Hmmm.. I must have you confused with Johnny_C 03/02/21 10:19:40 AM
#94621   The reading comprehension skills on this board is amazing. vinovista 03/02/21 09:26:09 AM
#94620   Well, I just looked at the Pedima webiste; Johnny_C 03/02/21 06:37:51 AM
#94619   For the record it no longer matters about Johnny_C 03/02/21 06:17:54 AM
#94618   Another at-home covid test got an EUA: Ballchinian5 03/02/21 12:36:41 AM
#94617   Generally as long as it does no harm IPwatcher 03/01/21 06:58:41 PM
#94616   "Holy Shazaam Batman, sounds like you are going vinovista 03/01/21 04:49:27 PM
#94615   Holy Shazaam Batman, sounds like you are going Johnny_C 03/01/21 02:51:11 PM
#94614   move to the head of the class ernie44 03/01/21 12:08:09 PM
#94613   From the web site: vinovista 03/01/21 11:09:24 AM
#94612   It's old news and based on the timing rawman 03/01/21 10:41:43 AM
#94611   Thanks! That seems to have cleared things up for vinovista 03/01/21 10:35:21 AM
PostSubject
Consent Preferences